Literature DB >> 18719913

Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.

Robin Goforth1, Aliasger K Salem, Xiaoyan Zhu, Suzanne Miles, Xue-Qing Zhang, John H Lee, Anthony D Sandler.   

Abstract

Anti-tumor vaccines capable of activating both CD4 and CD8 T cells are preferred for long lasting T cell responses. Induction of a tumor-specific T-cell response can be induced by tumor vaccines that target innate immunity. The ensuing T-cell response depends on efficient antigen presentation from phagocytosed cargo in the antigen presenting cell and is augmented by the presence of Toll-like receptor (TLR) ligands within the cargo. Biodegradable polymers are useful for vaccine delivery in that they are phagocytosed by antigen presenting cells (APCs) and could potentially be loaded with both the antigen and immune stimulatory TLR agents. This study was undertaken to evaluate the effect of poly lactic-co-glycolic acid (PLGA) polymer particles loaded with antigenic tumor lysate and immune stimulatory CpG oligonucleotides on induction of tumor specific immunity in a mouse model of melanoma. We found that after delivery, these immune stimulatory antigen loaded particles (ISAPs) efficiently activated APCs and were incorporated into lysosomal compartments of macrophages and dendritic cells. ISAP vaccination resulted in remarkable T cell proliferation, but only modestly suppressed tumor growth of established melanoma. Due to this discordant effect on tumor immunity we evaluated the role of regulatory T cells (Treg) and found that ISAP vaccination or tumor growth alone induced prolific expansion of tumor specific Treg. When the Treg compartment was suppressed with anti-CD25 antibody, ISAP vaccination induced complete antigen-specific immunity in a prophylactic model. ISAP vaccination is a novel tumor vaccine strategy that is designed to co-load the antigen with a TLR agonist enabling efficient Ag presentation. Targeting of T-reg expansion during vaccination may be necessary for inducing effective tumor-specific immunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18719913     DOI: 10.1007/s00262-008-0574-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  19 in total

Review 1.  Nano-enabled delivery of diverse payloads across complex biological barriers.

Authors:  Kathleen A Ross; Timothy M Brenza; Andrea M Binnebose; Yashdeep Phanse; Anumantha G Kanthasamy; Howard E Gendelman; Aliasger K Salem; Lyric C Bartholomay; Bryan H Bellaire; Balaji Narasimhan
Journal:  J Control Release       Date:  2015-08-24       Impact factor: 9.776

2.  In vivo depletion of CD4(+)CD25(hi) regulatory T cells is associated with improved antiviral responses in cats chronically infected with feline immunodeficiency virus.

Authors:  S Rochelle Mikkelsen; Stacie K Reckling; Erin A Egan; Gregg A Dean
Journal:  Virology       Date:  2010-05-14       Impact factor: 3.616

Review 3.  Nanovaccines for cancer immunotherapy.

Authors:  Yu Zhang; Shuibin Lin; Xiang-Yang Wang; Guizhi Zhu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-06-06

4.  Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.

Authors:  Joanna L Meadors; Yonghzi Cui; Qing-Rong Chen; Young K Song; Javed Khan; Glenn Merlino; Maria Tsokos; Rimas J Orentas; Crystal L Mackall
Journal:  Pediatr Blood Cancer       Date:  2011-04-01       Impact factor: 3.167

5.  Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans.

Authors:  Yun Lin; Li Zhang; Ann X Cai; Mark Lee; Wandi Zhang; Donna Neuberg; Christine M Canning; Robert J Soiffer; Edwin P Alyea; Jerome Ritz; Nir Hacohen; Terry K Means; Catherine J Wu
Journal:  J Clin Invest       Date:  2011-03-14       Impact factor: 14.808

6.  ANALYSIS OF DENDRITIC CELL STIMULATION UTILIZING A MULTI-FACETED NANOPOLYMER DELIVERY SYSTEM AND THE IMMUNE MODULATOR 1-METHYL TRYPTOPHAN.

Authors:  Kevin P Nikitczuk; Edmund C Lattime; Rene S Schloss; Martin L Yarmush
Journal:  Nano Life       Date:  2010-09-01

Review 7.  Tumor lysate-loaded biodegradable microparticles as cancer vaccines.

Authors:  Vijaya B Joshi; Sean M Geary; Brett P Gross; Amaraporn Wongrakpanich; Lyse A Norian; Aliasger K Salem
Journal:  Expert Rev Vaccines       Date:  2014-01       Impact factor: 5.217

Review 8.  Innovative strategies for co-delivering antigens and CpG oligonucleotides.

Authors:  Yogita Krishnamachari; Aliasger K Salem
Journal:  Adv Drug Deliv Rev       Date:  2009-01-19       Impact factor: 15.470

9.  Antigen-coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations.

Authors:  Caitlin D Lemke; Sean M Geary; Vijaya B Joshi; Aliasger K Salem
Journal:  Biomaterials       Date:  2013-01-11       Impact factor: 12.479

Review 10.  Therapeutic manipulation of immune tolerance in allergic disease.

Authors:  Mübeccel Akdis; Cezmi A Akdis
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.